Found 24 matching trials
Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
PHASE1This phase I trial studies the side effects and best dose of BCMA CART cell...
Location
Shenzhen Second People's Hospital,The first affiliated hospital of Shenzhen University
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
EARLY_PHASE1This is a single-arm, open-label, investigator-initiated trial (IIT) design...
Location
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
Universal CAR-T Cells Targeting Multiple Myeloma
PHASE1The aim of this study is to assess the feasibility, safety and efficacy of ...
Location
Shenzhen Geno-Immune Medical Institute
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
PHASE1This is a single-center, open-label, non-randomized, single-arm clinical tr...
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
PHASE1This is a single-center, open-label, non-randomized, single-arm clinical tr...
Location
Beijing GoBroad Hospital
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
PHASE1This research study is for people who have been waiting for a kidney transp...
Location
Massachusetts General Hospital: Transplantation (Site #: 71107)
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
N/AThe goal of this observational study is to learn about vaccine immunity in ...
Location
University Hospital Bern
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
NAThis is an open label, single-site, dose-escalation study in up to 18 parti...
Location
Hunan Siweikang Therapeutic Co.Ltd
Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease
EARLY_PHASE1This is an open-label, Phase I, investigator-initiated trial (IIT) designed...
Location
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
PHASE1This is an open label, Multi-center,dose-escalation study in up to 18 parti...
Location
Multiple Locations